← Leaderboards
Lauren Cole Peres
H. Lee Moffitt Cancer Ctr & Res Inst
$4,649,275
Attributed
$6,578,483
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2017–25$2.5M$1.9M$1.3M$625K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,578,483 · 7
By mechanism
R01$4,924,366 · 3
R00$722,106 · 1
U54$537,332 · 1
R56$299,995 · 1
K99$94,684 · 1
Top collaborators
- Brooke L Fridley4 shared
- Doris K Hansen2 shared
- Laura B. Oswald2 shared
- Rikki Cannioto1 shared
- Matthew B. Schabath1 shared
Most similar at H. Lee Moffitt Cancer Ctr & Res Inst
Same institution · by research overlap
- Stephanie L. Schmit$6,323,663
- Brooke L Fridley$4,952,468
- Kimberley T Lee$853,846
- Matthew B. Schabath$5,397,368
Others in their field
Other Emerging Leaders on “Epithelial Ovarian Cancer”
- Hui Shen · Van Andel Research Institute$3,373,085
- Nickolas Papadopoulos · Johns Hopkins University$3,027,729
- Andrew J. Gentles · Stanford University$2,526,750
- Cesar M Castro · Massachusetts General Hospital$2,239,343
- Charles Nicholson Landen · University Of Virginia$2,167,574
- Ursula Anne Matulonis · Dana-Farber Cancer Inst$2,129,847
Research focus
Epithelial Ovarian CancerMalignant Neoplasm Of OvaryOvarian NeoplasmMalignant NeoplasmsWomanTumorCellsDiagnosisCancer PatientCancer SurvivalMalignant Female Reproductive System NeoplasmImmuneCancer EpidemiologyEpidemiology StudyTumor MicroenvironmentCell TypeResourcesPopulation StudyRaceInflammationBiological MarkersSamplingTissuesPhenotype
Grant awards (17)
Survivorship in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-cell Therapy$690,260
R01 · FY2025 · CA
Methylomic basis of survival disparities among Black and White women with high-grade serous ovarian cancer$596,383
R01 · FY2025 · CA · contact PI
Spatial and Bayesian modeling methods for assessment of the tumor immune microenvironment and survival of women with ovarian cancer$533,867
R01 · FY2025 · CA
Project 2: The impact of biobehavioral factors and aspirin on ovarian cancer biology$147,264
U54 · FY2025 · CA · contact PI
Survivorship in Patients with Multiple Myeloma Treated with Chimeric Antigen Receptor T-cell Therapy$691,118
R01 · FY2024 · CA
Methylomic basis of survival disparities among Black and White women with high-grade serous ovarian cancer$623,971
R01 · FY2024 · CA · contact PI
Spatial and Bayesian modeling methods for assessment of the tumor immune microenvironment and survival of women with ovarian cancer$508,680
R01 · FY2024 · CA
Radiomic biomarkers for clinical decision support that predict patient outcomes in serous ovarian carcinoma$299,995
R56 · FY2024 · CA · contact PI
Project 2: The impact of biobehavioral factors and aspirin on ovarian cancer biology$183,487
U54 · FY2024 · CA · contact PI
Methylomic basis of survival disparities among Black and White women with high-grade serous ovarian cancer$706,049
R01 · FY2023 · CA · contact PI
Spatial and Bayesian modeling methods for assessment of the tumor immune microenvironment and survival of women with ovarian cancer$304,046
R01 · FY2023 · CA
Spatial and Bayesian modeling methods for assessment of the tumor immune microenvironment and survival of women with ovarian cancer$269,992
R01 · FY2023 · CA
Project 2: The impact of biobehavioral factors and aspirin on ovarian cancer biology$206,581
U54 · FY2023 · CA · contact PI
The Role of Inflammation in the Racial Disparities in Ovarian Cancer Survival$247,267
R00 · FY2020 · CA · contact PI
The Role of Inflammation in the Racial Disparities in Ovarian Cancer Survival$228,786
R00 · FY2019 · CA · contact PI
The Role of Inflammation in the Racial Disparities in Ovarian Cancer Survival$246,053
R00 · FY2018 · CA · contact PI
The Role of Inflammation in the Racial Disparities in Ovarian Cancer Survival$94,684
K99 · FY2017 · CA · contact PI